<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403517</url>
  </required_header>
  <id_info>
    <org_study_id>DEXLEV01</org_study_id>
    <secondary_id>2017-002652-81</secondary_id>
    <nct_id>NCT03403517</nct_id>
  </id_info>
  <brief_title>Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period</brief_title>
  <acronym>STEREO</acronym>
  <official_title>High Dose Steroids for Liver Resection - Effect on Complications and Endothelial Function in the Immediate Postoperative Phase - a Randomized, Doubleblind, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Several randomized clinical trials have shown beneficial effects of pre-operative&#xD;
      glucocorticoids on post-operative complications.&#xD;
&#xD;
      Studies on the effects of glucocorticoids on the postoperative recovery after liver-resection&#xD;
      show significantly lower markers of infection and liver damage, and some studies have shown a&#xD;
      shorter hospital stay.&#xD;
&#xD;
      Studies on the effects in the immediate postoperative phase are lacking.&#xD;
&#xD;
      Methods: Randomized, double-blind, controlled trial evaluating incidence of postoperative&#xD;
      complications in the immediate postoperative phase (and during admission) after open liver&#xD;
      surgery. Participants are randomized to either active treatment (methylprednisolone 10 mg/kg)&#xD;
      or control (8 mg dexamethasone), administered just prior to surgery.&#xD;
&#xD;
      All patients undergoing open liver resection at our institution are eligible. Included&#xD;
      patients are stratified according to extent of surgery into minor (&lt;3 segments) or major (â‰¥3&#xD;
      segments) group.&#xD;
&#xD;
      Patients in major group participate in Substudy I (markers of endothelial damage).&#xD;
&#xD;
      Patients operated between January and July 2018 participate in Substudy II (delirium).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-surgery, patients are traditionally observed and treated in post-anesthesia care units&#xD;
      (PACU) until they are discharged to the ward (or directly home) assessed by standardized&#xD;
      international discharge criteria.&#xD;
&#xD;
      The research project &quot;Why in PACU?&quot; (Rigshospitalet, Denmark), has since the beginning of&#xD;
      2016 systematically collected and analyzed procedure-related complications in the recovery&#xD;
      phase. The complications include pain, nausea/vomiting, circulatory and respiratory problems,&#xD;
      orthostatic intolerance and cognitive disorders. Common to all the above-mentioned&#xD;
      post-operative problems are the possible links to the inflammatory response caused by the&#xD;
      surgical trauma.&#xD;
&#xD;
      Glucocorticoids (GC) can in this context be central for the reduction of acute postoperative&#xD;
      organ dysfunctions, caused by the anti-inflammatory effect. In a number of different surgical&#xD;
      procedures, single dose, pre-operative glucocorticoids have been shown to reduce&#xD;
      post-operative nausea and vomiting (PONV), acute pain and need of opioids as well as&#xD;
      accelerate the convalescence. Meta-analyses also showed that single-dose administration of&#xD;
      glucocorticoids (methylprednisolone and dexamethasone) for surgical patients is safe as&#xD;
      opposed to long-term treatment.&#xD;
&#xD;
      Studies on pre-operative glucocorticoids before liver surgery have shown beneficial effects&#xD;
      in regards to markers of liver damage and infection, but studies on clinical outcomes in the&#xD;
      immediate post-operative phase are lacking.&#xD;
&#xD;
      The primary aim of this study is to investigate whether high dose pre-operative&#xD;
      glucocorticoids reduce complications in the immediate post-operative course.&#xD;
&#xD;
      The investigators will also perform two hypothesis-generating sub studies:&#xD;
&#xD;
        -  Sub study I - markers of endothelial dysfunction&#xD;
&#xD;
      The endothelial lining of blood vessels contributes to maintaining haemostasis, and damage&#xD;
      can increase risks of cardiovascular and thromboembolic complications. In a recent randomized&#xD;
      trial, pre-operative high dose glucocorticoids diminished circulating markers of endothelial&#xD;
      damage (after knee arthroplasty). In this study we will investigate whether this also applies&#xD;
      liver surgery, and if so, if there is any connection to cardiovascular and thromboembolic&#xD;
      complications.&#xD;
&#xD;
        -  Sub study II - delirium Studies on delirium after liver surgery show an incidence around&#xD;
           20%. It has not been investigated whether pre-operative glucocorticoids have an effect&#xD;
           on this incidence.&#xD;
&#xD;
      The investigators will investigate the incidence of emergence delirium and delirium during&#xD;
      the first postoperative day s after liver surgery.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      The &quot;Why in PACU?&quot; database shows that complications requiring treatment in PACU occur in up&#xD;
      to 40 % of patients after liver surgery. These complications are primarily respiratory and&#xD;
      circulatory.&#xD;
&#xD;
      A 50 % reduction in the number of patients with complications requiring treatment is regarded&#xD;
      clinically relevant. This will require a sample size of 174 patients, including 10 % dropout&#xD;
      (80 % power, 5% level of significans, superiority design). Patients will be stratified&#xD;
      according to extent of surgery, into minor or major resection.&#xD;
&#xD;
      The sub studies are hypothesis-generating, and are not subject to power calculations. Sub&#xD;
      study I will include all major resections, sub study II will include patients during the&#xD;
      first 5 months.&#xD;
&#xD;
      Analysis: Primary end point (complications in the two groups) is compared with chi square&#xD;
      test and described with odds ratio (95%CI). Level of significance is p=0,05 Standard&#xD;
      statistical analysis will include normally or near-normally distributed variables reported as&#xD;
      means and non-normally distributed variables as medians. Means will be compared using the&#xD;
      student's t test and medians using the Mann-Whitney U test. Differences in proportions among&#xD;
      categorical data will be assessed using Fischer's exact test. A p value &lt; 0.05 will represent&#xD;
      statistical significance for all comparisons.&#xD;
&#xD;
      Hypothesis: Preoperative GC administration will decrease the incidence of postoperative&#xD;
      complications and overall hospital length of stay following liver surgery. Preoperative GC&#xD;
      administration will decrease markers of endothelial dysfunction following major liver&#xD;
      surgery. Preoperative GC administration will decrease incidence of delirium following liver&#xD;
      surgery.&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      Data elements to be collected will include, but not be limited to:&#xD;
&#xD;
        -  Demographics (age, gender, height, weight, tobacco and alcohol consumption,&#xD;
           comorbidities, American Society of Anaesthesiology (ASA) score)&#xD;
&#xD;
        -  Preoperative chemotherapy, preoperative use of analgesics and/or other central&#xD;
           stimulants&#xD;
&#xD;
        -  Preoperative biochemistry&#xD;
&#xD;
        -  Diagnosis, procedure, surgery duration&#xD;
&#xD;
        -  Blood loss, transfusions, use of drain, hepatic inflow occlusion (length of)&#xD;
&#xD;
        -  Postoperative pain, nausea, sedation and vitals, every 30 minutes until transfer to ward&#xD;
&#xD;
        -  Postoperative pain, nausea, mood and quality of sleep, self reported, every day until&#xD;
           discharge or postoperative day 5 (what comes first)&#xD;
&#xD;
        -  Postoperative use of analgesics and anti emetics until discharge or postoperative day 5&#xD;
           (what comes first)&#xD;
&#xD;
        -  Complications (hepatic failure, ascites, intraabdominal collection, postoperative&#xD;
           bleeding, bile leak, bowel obstruction, wound dehiscence, reoperations, pleural&#xD;
           effusion, pulmonary embolus, deep venous thrombosis, infections, cardiac events,&#xD;
           cerebral events, other causes of prolonged hospital stay)&#xD;
&#xD;
        -  3-minute Diagnostic Confusion Assessment Method (3D-CAM), postoperative day 0 (all) 1-3&#xD;
           (major resections)&#xD;
&#xD;
        -  Endothelial markers (Syndecan-1, soluble thrombomodulin, SE-selectin, vascular&#xD;
           endothelial growth factor (VEGF) postoperative day0-3 (major resections)&#xD;
&#xD;
        -  Hospital stay, length of stay in PACU&#xD;
&#xD;
        -  Mortality (30 days)&#xD;
&#xD;
      The study is not placebo-controlled since the positive effects of dexamethasone 8 mg on PONV&#xD;
      have been shown in numerous trials, and is already being administered to all patients at the&#xD;
      clinic. It would therefore not be ethically correct to withdraw from this practise.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Actual">September 28, 2020</completion_date>
  <primary_completion_date type="Actual">August 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complications, Post-anesthesia Care Unit (PACU)</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Number of patients with any complication at any time, during stay in the PACU. Complications according to DASAIMS discharge criteria (modified Aldrete criteria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy I: Markers of Endothelial Dysfunction</measure>
    <time_frame>post-operative days 0 to 3</time_frame>
    <description>Amount of endothelial markers (Syndecan-1, soluble thrombomodulin, SE-Selectin, vascular endothelial growth factor (VEGF) )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy II: Delirium</measure>
    <time_frame>5 days</time_frame>
    <description>Number of patients with post-operative cognitive impairment, according to 3-minute diagnostic confusion assessment method (3D-CAM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>any cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Complication Rate</measure>
    <time_frame>30 days</time_frame>
    <description>any complications, 30 day morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Stay</measure>
    <time_frame>3 months</time_frame>
    <description>from operation to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU Stay</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>from operation to discharge from PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at Movement</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>every 60 minutes, during stay in PACU. Numeric Rating Scale (NRS 0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, Abdominal (Postoperative)</measure>
    <time_frame>up to five days</time_frame>
    <description>During admission, self reported. Numeric Rating Scale (NRS 0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>up to five days</time_frame>
    <description>During admission, self reported. (Light, none, moderate, heavy nausea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Requirements</measure>
    <time_frame>up to five days</time_frame>
    <description>All analgesics other than standard medication, during admission. From Medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiemetic Requirements</measure>
    <time_frame>up to five days</time_frame>
    <description>All antiemetics other than standard medication, during admission. From Medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALAT</measure>
    <time_frame>up to five days</time_frame>
    <description>impact on ALAT (alanin-aminotransferase) post surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>up to five days</time_frame>
    <description>impact on bilirubin post surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>up to five days</time_frame>
    <description>impact on INR (International Normalized Ratio) post surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Complication, Postoperative</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg, single preoperative infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 mg dexamethasone, single preoperative infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>solu-medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age minimum 18&#xD;
&#xD;
          -  Planned open liver resection (with or without combined ablation and/or&#xD;
&#xD;
          -  cholecystectomy)&#xD;
&#xD;
          -  Able to participate (self report pain/nausea)&#xD;
&#xD;
          -  Understands danish/english, or has an interpreter during admission&#xD;
&#xD;
          -  Signed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ALPPS (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy)&#xD;
             procedure&#xD;
&#xD;
          -  Combined ventral herniotomy with implantation of mesh&#xD;
&#xD;
          -  Combined with operation on tumor in other organs&#xD;
&#xD;
          -  Insulin dependent diabetes&#xD;
&#xD;
          -  Current (&lt;10 days) treatment with systemic glucocorticoids and/or immunosuppressive&#xD;
             treatment (not including inhalations)&#xD;
&#xD;
          -  Epidural anesthesia not feasible&#xD;
&#xD;
          -  Pregnancy/breastfeeding&#xD;
&#xD;
          -  Allergy toward study medication&#xD;
&#xD;
          -  Inoperability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <results_first_submitted>December 8, 2020</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Kristin Julia Steinthorsdottir</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>steroids</keyword>
  <keyword>glucocorticoids</keyword>
  <keyword>liver surgery</keyword>
  <keyword>hepatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03403517/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03403517/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Methylprednisolone</title>
          <description>10 mg/kg, single preoperative infusion&#xD;
Methylprednisolone: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone</title>
          <description>8 mg dexamethasone, single preoperative infusion&#xD;
Dexamethasone: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methylprednisolone</title>
          <description>10 mg/kg, single preoperative infusion&#xD;
Methylprednisolone: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone</title>
          <description>8 mg dexamethasone, single preoperative infusion&#xD;
Dexamethasone: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="11"/>
                    <measurement group_id="B2" value="64" spread="12"/>
                    <measurement group_id="B3" value="65" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complications, Post-anesthesia Care Unit (PACU)</title>
        <description>Number of patients with any complication at any time, during stay in the PACU. Complications according to DASAIMS discharge criteria (modified Aldrete criteria)</description>
        <time_frame>up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylprednisolone</title>
            <description>10 mg/kg, single preoperative infusion&#xD;
Methylprednisolone: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>8 mg dexamethasone, single preoperative infusion&#xD;
Dexamethasone: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Complications, Post-anesthesia Care Unit (PACU)</title>
          <description>Number of patients with any complication at any time, during stay in the PACU. Complications according to DASAIMS discharge criteria (modified Aldrete criteria)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.213</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.859</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.682</ci_lower_limit>
            <ci_upper_limit>1.082</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Substudy I: Markers of Endothelial Dysfunction</title>
        <description>Amount of endothelial markers (Syndecan-1, soluble thrombomodulin, SE-Selectin, vascular endothelial growth factor (VEGF) )</description>
        <time_frame>post-operative days 0 to 3</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Substudy II: Delirium</title>
        <description>Number of patients with post-operative cognitive impairment, according to 3-minute diagnostic confusion assessment method (3D-CAM)</description>
        <time_frame>5 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>any cause mortality</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylprednisolone</title>
            <description>10 mg/kg, single preoperative infusion&#xD;
Methylprednisolone: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>8 mg dexamethasone, single preoperative infusion&#xD;
Dexamethasone: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>any cause mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Complication Rate</title>
        <description>any complications, 30 day morbidity</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylprednisolone</title>
            <description>10 mg/kg, single preoperative infusion&#xD;
Methylprednisolone: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>8 mg dexamethasone, single preoperative infusion&#xD;
Dexamethasone: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Total Complication Rate</title>
          <description>any complications, 30 day morbidity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.977</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.557</ci_lower_limit>
            <ci_upper_limit>1.715</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Stay</title>
        <description>from operation to discharge</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylprednisolone</title>
            <description>10 mg/kg, single preoperative infusion&#xD;
Methylprednisolone: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>8 mg dexamethasone, single preoperative infusion&#xD;
Dexamethasone: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Stay</title>
          <description>from operation to discharge</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="77" upper_limit="147"/>
                    <measurement group_id="O2" value="102" lower_limit="93" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.160</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PACU Stay</title>
        <description>from operation to discharge from PACU</description>
        <time_frame>up to 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylprednisolone</title>
            <description>10 mg/kg, single preoperative infusion&#xD;
Methylprednisolone: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>8 mg dexamethasone, single preoperative infusion&#xD;
Dexamethasone: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>PACU Stay</title>
          <description>from operation to discharge from PACU</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" lower_limit="143" upper_limit="320"/>
                    <measurement group_id="O2" value="186" lower_limit="156" upper_limit="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain at Movement</title>
        <description>every 60 minutes, during stay in PACU. Numeric Rating Scale (NRS 0-10)</description>
        <time_frame>up to 24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain, Abdominal (Postoperative)</title>
        <description>During admission, self reported. Numeric Rating Scale (NRS 0-10)</description>
        <time_frame>up to five days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea</title>
        <description>During admission, self reported. (Light, none, moderate, heavy nausea)</description>
        <time_frame>up to five days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Requirements</title>
        <description>All analgesics other than standard medication, during admission. From Medical record.</description>
        <time_frame>up to five days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antiemetic Requirements</title>
        <description>All antiemetics other than standard medication, during admission. From Medical record.</description>
        <time_frame>up to five days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALAT</title>
        <description>impact on ALAT (alanin-aminotransferase) post surgery</description>
        <time_frame>up to five days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin</title>
        <description>impact on bilirubin post surgery</description>
        <time_frame>up to five days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INR</title>
        <description>impact on INR (International Normalized Ratio) post surgery</description>
        <time_frame>up to five days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>40 hours after drug administration</time_frame>
      <desc>According to GCP definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Methylprednisolone</title>
          <description>10 mg/kg, single preoperative infusion&#xD;
Methylprednisolone: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone</title>
          <description>8 mg dexamethasone, single preoperative infusion&#xD;
Dexamethasone: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>variceal bleeding</sub_title>
                <description>patient with cirrosis, postoperative gastriintestinal bleeding due to esophageal varices</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>bile lesion</sub_title>
                <description>one suspected and one intraoperative lesion (due to tumor ingrowth)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristin steinthorsdottir</name_or_title>
      <organization>Rigshospitalet</organization>
      <phone>004531666112</phone>
      <email>kjs@dadlnet.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

